| 1 |
31773494 | Correction to: Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. | 2020 Jan |
1 |
| 2 |
27002825 | Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. | 2016 |
3 |
| 3 |
22512726 | The effect of some antineoplastic agents on glutathione S-transferase from human erythrocytes. | 2013 Aug |
1 |
| 4 |
23252950 | Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. | 2013 Jan |
1 |
| 5 |
22012257 | Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients. | 2012 Apr |
1 |
| 6 |
18496131 | Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. | 2008 Jun |
2 |
| 7 |
16995867 | Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. | 2006 Oct |
1 |
| 8 |
15142875 | Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. | 2004 Sep 1 |
2 |
| 9 |
12516103 | Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. | 2003 Mar 1 |
1 |
| 10 |
7786310 | Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. | 1995 May 26 |
4 |
| 11 |
7728738 | Erythrocyte antioxidant enzyme activity in CMF treated breast cancer patients. | 1994 Oct |
1 |
| 12 |
7954469 | Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. | 1994 Dec 1 |
3 |
| 13 |
1419639 | Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. | 1992 Nov |
3 |
| 14 |
1680689 | Chemoresistance in breast tumors. | 1991 |
1 |